# Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours

> **NCT05920408** · PHASE1,PHASE2 · TERMINATED · sponsor: **Exscientia AI Limited** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** EXS21546

## Key facts

- **NCT ID:** NCT05920408
- **Lead sponsor:** Exscientia AI Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-11
- **Primary completion:** 2023-09-27
- **Final completion:** 2023-10-23
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Emerging data demonstrates challenge for EXS21546 to reach suitable therapeutic index.
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05920408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05920408, "Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05920408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*